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MANAGING ALLOIMMUNIZATION, DELAYED HEMOLYTIC 
TRANSFUSION REACTIONS, AND HYPER-HEMOLYSIS IN SICKLE CELL 
DISEASE 
ANQI GUO 
ABSTRACT 
Sickle cell disease (SCD) is an inherited blood disorder in which polymerization 
of a mutated form of hemoglobin results in a sickled shape of red blood cells, leading to 
anemia due to premature destruction of RBCs. Other morbidities include end-organ 
damage, pain attacks known as “sickle cell crisis,” bacterial infections, and stroke. 
Transfusion therapy remains a necessary treatment of sickle cell disease. Transfusions 
given to lower the levels of sickle RBCs and viscosity have shown to decrease the risk of 
stroke by 90% during clinical trials.  
However, chronically transfused patients can become alloimmunized and develop 
delayed hemolytic transfusion reactions (DHTR), a life-threatening condition. The 
presentation of DHTR can vary, and its severity is unpredictable. In the most severe 
cases, patients destroy their own RBCs along with the transfused RBCs, a condition 
known as hyper-hemolysis. Additional transfusions can aggravate these symptoms and 
lead to death. Clinicians’ awareness of DHTR events is poor because its clinical 
presentations mimic those of vaso-occlusive crisis.  Furthermore, immunohematology at 
times detect no newly formed antibodies. Mortality due to DHTR have been reported to 
be as high as 11.5%.  
Currently, 5.4 million people suffer from sickle cell disease. An overwhelming 
  v 
80% of SCD occurs in Sub-Saharan Africa, while also occurring frequently in people of 
African origin living in other parts of the world. Annually, over 100,000 patients are 
affected by SCD, utilizing over one billion dollars per year in healthcare costs. Lastly, 
current projections estimate that by 2050 the number of newborns with sickle cell disease 
will exceed 400,000.  
While there are no drugs that specifically target DHTR, immunosuppressants 
such as intravenous immunoglobulins, steroids, eculizumab, and tocilizumab have shown 
to improve outcomes in DHTR. However, these treatments may prove to be insufficient. 
Moreover, numerous adverse health effects are associated with using 
immunosuppressants, including exacerbation of vaso-occlusive pain and hemolytic 
anemia already present in SCD patients. Currently, alloimmunization can be prevented by 
extended-matching of blood antigen, increasing blood donations from Africa Americans 
and other minority groups, and the use of rituximab. While hematopoietic stem cell 
transplantation remains a viable alternative to transfusing therapy, it remains highly 
under-utilized. 
This literature review aims to evaluate the current prevention and treatment 
methods used to manage DHTR to expose gaps in knowledge and identify ways to 
improve clinical outcomes in SCD patients. Results suggest:  
(1) While it is not cost-effective to implement extended matching in all SCD 
patients, there is potential in strategies to increase blood donation in minority groups. 
Genotyping of blood antigens may also be considered.    
(2) Treatment options are sorely lacking for DHTR. Case studies document 
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positive outcomes using immunosuppressants, but there are few clinical trials and 
evidence-based studies to confirm their efficacy in larger cohorts. 
(3) Effective treatment of DHTR relies on prospective studies that further 
elucidate the pathophysiology of alloimmunization and DHTR.  
(4) The lack of effective treatments for DHTR can be attributed to structural 
violence. Advocacy and awareness are instrumental in improving care for DHTR and 
SCD.    
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 1 
INTRODUCTION 
 
Sickle cell disease (SCD) is an inherited blood disorder in which 
polymerization of a mutated form of hemoglobin results in a sickled shape of red blood 
cells (RBC), leading to anemia due to the premature destruction of RBCs. A single amino 
acid substitution (Glutamine to Valine) at the sixth position of the beta chain of 
hemoglobin S (HbS) results in HbS instability and polymerization, causing RBCs to form 
a rigid, sickle shape (Eaton & Bunn, 2017). The loss of RBC elasticity leads to adhesion- 
medicated vaso-occlusion, where deformed RBCs adhere to each other and block flow in 
small blood vessels. This results in devastating health complications such as end-organ 
damage, pain attacks known as “sickle cell crisis,” bacterial infections, and stroke.  
A person is known to have the sickle cell trait (SCT) when only one copy of the sickle 
cell gene is present (Telen et al., 2019).  Individuals with SCT are able to lead normal 
lives without any SCD complications. Approximately 10% of American Americans (AA) 
and more than 100 million worldwide are estimated to carry the SCT (Yazdanbakhs et al., 
2012) 
Currently, 5.4 million people suffer from sickle cell disease, while 43 million 
have the sickle cell trait.  An overwhelming 80% of sickle cell disease occurs in Sub-
Saharan Africa, while also occurring frequently in people of African origin living in other 
parts of the world (Rees et al., 2010). Patients living in developed countries can expect to 
live beyond their 50s with adequate medical treatment. However, in low-income 
countries such as Africa, 90% of patients die before their fifth birthday (Gravitz & 
Pincock, 2014). In the United States, SCD prevalence is 1 in every 500 AA births, 1 in 
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every 36,000 Hispanic-American births, and 1 in every 100,000 Caucasian births 
(Hassell, 2010). Annually, over 100,000 patients are affected by SCD (Bunn, 1997), 
utilizing over one billion dollars per year in healthcare costs (Kauf et al., 2009). Lastly, 
current projections estimate that by 2050 the number of newborns with sickle cell disease 
will exceed 400,000 (Aslam et al., 2018). 
Approaches to management of SCD can be separated into five categories: 
supportive, preventative, symptomatic, abortive, and curative therapy. Supportive 
management typically includes the essential components for good health, such as a 
balanced diet, sleep, hydration, and folic acid. Preventative management includes 
avoidance of stressful situations, vaccination, hemoglobin F induction with hydroxyurea, 
and transfusion. Symptomatic management aims to alleviate the symptoms as it occurs 
via transfusion, pain medication, and antibiotics (Ballas et al., 2012). Lastly, stem cell 
transplantation and gene therapy hold promising potential in reversing the 
pathophysiological process of SCD (Telen et al., 2019).  
Blood transfusion is a life-saving treatment as it provides normal RBCs and 
increases oxygen distribution to tissues to decrease morbidity and mortality for SCD 
patients. Studies have demonstrated transfusions dramatically reduce the risk of stroke 
(Adams et al., 1998) and cerebral infarction (DeBaun et al., 2014) in children suffering 
from SCD.  In clinical trials with SCD patients, transfusions to lower the percentage of 
sickle RBCs and blood viscosity decreased the risk of stroke by 90%.  
60% to 90% of SCD patients will receive transfusions in their lifetime (Walter et 
al., 2009).  However, chronic transfusions can lead to RBC alloimmunization in 
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approximately 20% to 50% of  SCD patients (Yazdanbakhsh et al., 2012). 
Alloimmunization occurs when patients develop antibodies against transfused RBCs. 
These antibodies are usually directed against antigens expressed on RBCs of white 
persons, as they consist the majority of blood donors in Western countries (Vichinsky, 
2001). Finding compatible units lacking these antigens can be time laborious and cause 
transfusion delays.  
Delayed hemolytic transfusion reaction (DHTR) is the most life-threatening 
consequence of RBC alloimmunization. Among SCD patients receiving blood 
transfusions, between 4% to 11% have reported DHTR and its associated health effects.  
Its clinical presentations include acute hemolysis (hemoglobinuria, jaundice, and pallor), 
vaso-occlusive crisis (pain, fever, acute chest syndrome), anemia, and reticulocytopenia. 
The symptoms of DHTR present in a wide spectrum, and it is extremely difficult to 
predict its severity (Montalembert et al., 2011).  
In the most severe case of DHTR, hyper-hemolysis can occur, a poorly 
understood condition where the transfused and patient’s RBCs are destroyed 
(Yazdanbakhsh et al., 2012). Hemoglobin (Hb) level becomes lower than pre-transfusion 
levels, exacerbating anemia and SCD symptoms. Hyper-hemolysis can induce multiple 
organ failure (MOF) and death. Antibody screening detects alloantibodies (against blood 
groups) or autoantibodies (against self or unknown antigen). Interestingly, there are cases 
where antibodies are not detected. Furthermore, the frequency and mortality rates of 
DHTR may be underreported because DHTRs are commonly misdiagnosed as vaso-
occlusive crises (VOC). 
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SPECIFIC AIMS 
 
The uncertainty surrounding DHTR’s exact mechanism of action complicates 
finding the best treatment approach. Currently, there are no guidelines to diagnose and 
treat DHTR with hyper-hemolysis. The standard treatment consists of corticosteroids, 
intravenous immunoglobins (IVIg), and avoidance of additional transfusions (Lee et al., 
2019). Prevention of alloimmunization is especially challenging as there are cases of 
DHTR where antibodies are not detected. Given these complications and challenges in 
treating DHTR with hyper-hemolysis in SCD patients, this literature review aims to:  
1. Highlight the various prevention and treatment methods currently used to address 
alloimmunization, DHTR,  and hyper-hemolysis.  
2. Evaluate each method using data from case studies, meta-analyses, surveys, and 
observational studies.     
3. Identify gaps of knowledge in prevention and treatment.  
4. Conclude with future directions and recommendations to optimally manage 
DHTR in SCD patients. 
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BACKGROUND 
 
Pathophysiology of Red Blood Cell Alloimmunization 
 
Antigenic differences between donor and recipient RBCs are the initial trigger of 
alloimmunization. RBC alloimmunization can be summarized in five steps (Figure 1):  
1. RBC antigen recognition, processing, and presentation by human leukocyte 
antigen (HLA) Class II to T-cell Receptor   
2. Activation of CD4 helper T cells  
3. Interaction of B and T cells  
4. Differentiation of B cells into plasma cells  
5. Production of antibodies by plasma cells  
Yazdanbakhsh et al. (2015)  suggest heightened immune effector cell responses 
and impaired regulatory networks drive antibody production during alloimmunization in 
SCD patients. Altered T cell immunoregulation and higher follicular T cell responses that 
increase antibody production was shown in alloimmunized SCD patients. Chronically 
transfused SCD patients reported reduced peripheral regulatory T cell (Treg) suppression 
and altered T helper cells (Th). These patients also demonstrated higher inflammatory 
cytokine (INF-alpha) and lower anti-inflammatory cytokine (IL-10) levels 
(Yazdanbakhsh, 2015). These findings support a model where SCD alloimmunization is 
due to a generalized immune dysregulation with an imbalance between Treg and Th cells 
and an increase in antibody production. It is likely alloimmunized SCD patients are 
unable to turn off their pro-inflammatory state in response to their hemolytic state, which 
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increases the risk of further alloimmunization (Yazdanbaksh et al., 2017; Platt, 2000)
 
 
 
Figure 1. Immune response to RBC antigens in alloimmunized versus non- 
alloimmunized patients. The yellow specifies possible interventions to prevent 
alloimmunization and treatment of DHTR. Figure taken from (Yazdanbakhsh et al., 
2012).  
 
 
It is important to note that not all transfused SCD patients develop antibodies, 
suggesting that alloimmunized patients may be a genetically distinct group with increased 
susceptibility to RBC sensitization. However, even within patients with inherited risks, 
only 30% will make antibodies, suggesting that host susceptibility factors and nature of 
the disease may also play a role in alloimmunization (Higgins & Sloan, 2008).  
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Factors Influencing Red Blood Cell Alloimmunization  
 
Antigenic differences between donor and recipient RBCs  
Racial antigenic differences play a crucial role in the increased alloimmunization 
in SDC patients compared with other transfused populations. Table 1 illustrates the 
numerous antigenic differences between white general blood donors and recipients of 
predominately African descent. C, E, K, Fya, Jkb, and S antigens are expressed more in 
whites than persons of African descent. In parallel, antibodies against these antigens are 
most frequently identified in SCD patients (Rosse et al., 1990). 
 The currently published rates of alloimmunization for SCD are between 20% to 
50% in selected cohorts in US and France (Yazdanbakhsh et al., 2012). This is 
significantly higher than alloimmunization rates in SCD patients in Uganda (6.1%) and 
Jamaica (2.6%), where donors and patients are racially more similar (Natukunda et al., 
2010; Olujohungbe et al., 2001). However, it can be argued that lower alloimmunization 
rates is due to lower usage of blood products in these countries.  In thalassemia patients, a 
population that is also frequently transfused but are more racially similar to white donors,  
alloimmunization is approximately 10% (Gupta et al., 2011). In contrast, 
alloimmunization increased to 22% in a majority Asian thalassemia patient population 
(Singer et al., 2000).   
Rh variants between whites and persons of African descent illustrated an 
additional level of complexity in matching compatible RBC units for SCD patients. 
Individuals of African descent have a greater genetic variation of the Rh locus and may 
have Rh variants that lack epitopes of normal antigen (Table 1). These partial Rh variants 
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can still cause alloimmunization to occur even when receiving Rh matched units because 
anti-Rh antibodies against the missing epitopes develop when transfused with donor 
blood carrying the normal antigen (Yazdanbakhsh et al., 2012). Studies have shown that 
while using Rh (D, C, E, c, e) and K matched blood, approximately 45% of chronically 
and 12% of episodically transfused patients still became alloimmunized  Chou et al., 
2013, Silvy et al., 2014).  
Increased alloimmunization also occurs when the recipient lacks the “high 
incidence antigen,” an antigen that is commonly expressed in almost all donor RBCs. 
SCD patients with rare blood types negative for Hrs, HrB, RH56, Jsb , or U are at risk for 
increased alloimmunization as they lack the “high incidence antigen” (Pirenne, 2003). 
Individuals with rare blood groups can develop antibodies against all common RBCs 
carrying the “high incidence antigen,”  potentially leading to severe cases of DHTR 
(Pirenne, 2019). Lastly, it is complicated to treat SCD patients with rare blood types, as 
many health facilities lack the appropriate antigen-negative blood.   
Table 1. Differences in blood groups between recipients and donors. All blood 
antigen frequencies have been obtained from The Blood Group Antigen “FactsBook.”  
 
Category  % in white donors  % in black recipients  
Common Antigens    
ABO group    
A 43 27 
B 9 20 
O 44 49 
AB 4 4 
RH   
D 88 92 
C 68 27 
E 29 20 
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c 80 96 
e 98 98 
KEL    
K 9 2 
FY   
Fya  66 10 
Fyb  83 23 
JK    
Jka  77 92 
Jka 74 49 
MNS   
S 51 31 
s 89 93 
Partial RH antigens    
Partial D among D+ 1  7 
Partial C Among C+ 0 30  
Partial e among e+ 0 2 
Low incidence antigens    
VS (RH20)  0.01 24-40 
sa (KEL6)  0.01 20 
Rare blood groups    
U negative (MNS:−5)  0 1 
Hrs negative (RH:−18)  0 0.1 
HrB negative (RH:−34)  0 0.1 
RN (RH:−46)  0 0.1 
Jsb negative (KEL:−7)  0 1 
 
 
Sickle Cell Disease Specific Susceptibility Factors  
SCD presents with a chronic inflammation state indicated by inflammatory 
cytokines (IL-1, IL-6, and IFN-gamma), increased C reactive proteins, and white blood 
cell (WBC) count (Hibbert et al., 2005; Jison et al., 2004). SCD can manifest into a 
severe clinical complication called VOC and ischemic pain (Uwaezuoke et al., 2018). 
VOC is indicated by increased neutrophil chemotaxis, monocyte phagocytosis, 
production of IL-6, and IFN-gamma (Pathare et al., 2004).  
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It has been previously demonstrated that viral-like inflammatory stimulus can 
enhance alloimmunization in murine models (Hendrickson et al., 2007). Moreover, SCD 
patients showed increased alloimmunization following transfusion for acute 
inflammatory complications (Fasano et al., 2015).  Lastly, febrile transfusion reactions, 
an inflammatory condition where the patient’s immune system attacks transfused 
lymphocytes, enhance alloimmunization in humans (Yazer et al., 2009). These studies 
support the notion that the inflammatory nature of SCD creates an altered alloimmunized 
potential.  
 
Frequency of RBC alloimmunization  
The published rates of alloimmunization in SCD patients are between 20% to 
50%, compared with 3% to 5% in transfused patients (Balbuena-Merle & Hendrickson, 
2019; Karafin et al., 2018). RBC alloimmunization prevalence can be higher than 
published data due to alloantibodies falling below detectable levels, lack of mandated 
post-transfusion antibody screening, and lack of complete medical records due to patients 
receiving care at different health facilities (Unni et al., 2014). Currently in the United 
States, there is no countrywide RBC alloantibody registry, making it difficult for 
hospitals to keep track of a patients’ alloantibody history. 
The morbidity and mortality due to RBC alloimmunization are not only under-
studied but also under-reported. For example, in the United States, nonfatal complications 
from SCD alloimmunization are not required to be reported to the FDA. The reporting of 
deaths due to transfusion is required in most countries. However, SCD deaths due to 
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transfusion complications may not be immediately and directly attributable to 
transfusion. Lastly, there are variations of reporting transfusion morbidities and 
mortalities across different countries (Balbuena-Merle & Hendrickson, 2019).  
 
High and Low Responders  
  Not every transfused SCD patient makes alloantibodies in antigenic mismatch 
situations. Fortunately, many SCD patients receive hundreds of blood units without 
developing any antibodies. Thus, high and low responders can be separated in this patient 
population, but precise cutoffs delineating the two have not yet been identified. The prior 
immunological status of the patient has some predictive value. A patient who previously 
developed antibodies post transfusion can be considered a high responder (Pirenne, 
2019).  
 
Alloimmunization Can Lead to DHTR  
 Evanescence occurs when alloantibodies fall below levels of detection using 
traditional blood banking methodologies. Patients then can be exposed to seemingly 
“safe” blood containing antigens that they have been previously sensitized to. This can 
lead to DHTR and hyper-hemolysis, which can be particularly dangerous to SCD patients 
who already have endogenous RBCs with shorter circulatory half-life. The high 
prevalence of alloimmunization in SCD patients may be attributed to the frequency of 
blood transfusions a patient receives throughout their lifetime. SCD patients are usually 
exposed to RBCs with foreign antigens from a variety of donors (Balbuena-Merle & 
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Hendrickson, 2019). The result of remote antigen exposure is the development of 
alloantibodies in SCD patients, which is not often detected in pre-transfusion screening 
(Yazdanbakhsh et al., 2012). Along with the lack of detailed and longitudinal transfusion 
records, a SCD patient can be put at risk for alloimmunization and the resulting 
transfusion complications. 
 
Alloantibodies and Autoantibodies  
   In the cases where antibodies are identified (approximately 70%), half are 
alloantibodies linked to known blood group polymorphisms (Habibi et al., 2016).  In 
post-DHTR cases, the most frequently identified antibodies are against Fya, Jkb, and S. In 
half of these cases, at least two antibodies were found in patients with a previous history 
of alloimmunizations. Furthermore, alloimmunization has also be associated with RH 
variant carriers (DAR, DIIIa, DIVa, and DAU), low-incidence antigens (Goa, Jsa Cob), 
and rare RH blood group (HrS, HrB) can lead to alloimmunization (Yazdanbakhsh et al., 
2012).  
Autoantibodies, antibodies against self-antigens, consist of the second half 
(Habibi et al., 2016). Autoantibody medicated DHTR with hyperhemolysis is supported 
by two studies (Castellino et al., 1999; Aygun et al., 2002). In these cases, autoantibodies 
are hard to characterize because they appear as panagglutinins, an antibody that reacts 
against all reagents in an antibody panel (Yazdanbakhsh et al., 2012) 
Interestingly, autoantibodies can be a risk factor in the formation of alloantibodies 
in chronically transfused SCD patients. In a study with over 600,000 patients across 12 
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hospitals, 42.2% of patients with RBC autoantibodies had at least one alloantibody 
(Karafin et al., 2018). In cases where autoantibodies develop during DHTR, extended 
matching cannot be used as a prevention method. Instead, rituximab administration 
before transfusion can be used to prevent alloimmunization (Pirenne et al., 2017).  
 Lastly, a subset of DHTR presents with no detectable antibodies. The exact 
mechanism of this phenomenon is still poorly understood, thus challenging to treat or 
prevent.  It is impossible to identify patients at risk for a first or recurrent episode of 
DHTR.  
 
Mechanisms of Delayed Hemolytic Transfusion Response  
 DHTR is a severe consequence of  RBC alloimmunization.  A DHTR occurs 
when a patient receives RBCs expressing an antigen which the patient is unknowingly 
sensitized against. Within four days post-transfusion, the patients produce antibodies that 
bind to the transfused RBCs. This leads to their destruction via phagocytosis and 
complement-mediated hemolysis (Pirenne et al., 2017).   
DHTRs can occur between 24 hours to ten days post transfusion. It is 
characterized by a significant drop in Hb levels, exacerbating SCD symptoms and degree 
of anemia. Commonly, patients also develop severe reticulocytopenia, a decrease in 
immature RBCs. This requires the patient to receive additional transfusions, which may 
worsen their hemolytic symptoms (Pirenne et al., 2017; Yazdanbakhsh et al., 2012). 
DHTR can present with a wide range of symptoms, but it is difficult to predict its 
severity. In severe cases, the patient’s own RBCs are also destroyed, a phenomenon 
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referred to as hyper-hemolysis. The general mechanism of hemolytic transfusion 
response is illustrated below in Figure 2. 
 
 
 
Figure 2. General mechanism of hemolytic transfusion response.  
Agglutination is the process where an antibody binds to its corresponding antigen, 
forming a large clump of particles. Panel (B) illustrates when agglutination as a result of 
antigenic mismatch. Figure taken from 
(https://arimmuneresponseassignment.weebly.com/report.html)  
 
 
Mechanism of Intravascular Hemolysis  
Intravascular hemolysis occurs when the RBCs ruptures within the vasculature, 
releasing free heme and Hb into the plasma. Free Hb is vulnerable to be oxidized as it no 
longer has anti-oxidant sentries that are normally available in RBCs. However, free Hb 
can bind to haptoglobin, a plasma glycoprotein, to form the hemoglobin-haptoglobin 
complex. Only during hyper-hemolytic or chronic hemolysis conditions when 
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haptoglobin becomes depleted, free Hb is oxidized to ferric Hb and further dissociates 
into heme, iron, and globin (Schaer et al., 2014; Gladwin et al., 2012).  
Figure 3 illustrates various ways intravascular hemolysis contributes to 
inflammatory injury, vasculopathy, and vaso-occlusion. Free hemoglobin drives Fenton 
reactions to produce oxidants. Free heme further activates the release of placenta growth 
factor (PGIF) and endothelin-1 (ET-1) that contribute to endothelial dysfunction, platelet 
activation, and pulmonary hypertension. Heme activates the production of reactive 
oxidative species (ROS), neutrophil extracellular traps (NET), and inflammatory 
cytokines, other mediators that promote the expression of adhesion receptors and ligands 
on endothelium and RBCs. The activated endothelium then interacts with platelets, 
neutrophils, and sickle RBCs to produce vaso-occlusion and acute chest syndrome (Kato 
et all., 2017 ) 
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Figure 3. Contribution of intravascular hemolysis to vasculopathy and vaso-
occlusion. Figure taken from (Kato et al, 2017) 
 
 
Free heme can also bind to another plasma glycoprotein, hemopexin, and travel to 
the liver, spleen, and bone marrow to be phagocytized by macrophages during the 
process of extravascular hemolysis.  
 
Complement Activation during Intravascular Hemolysis     
During DHTR, intravascular hemolysis may activate the complement cascade via 
the classical pathway or the alternative pathway (Dumas et al., 2016). The classical 
pathway is activated by immune complex formation (antibody binds to RBCs), leading to 
C1 complex association. The alternative pathway is activated by the hydrolysis of C3 into 
C3(H20). These two pathways converge with when C3 convertase converts C3 into C3a 
and C3b. The cascade continues to make C5b-9, also known as the membrane attack 
complex (MAC). The MAC destroys the targeted cell by disrupting its membrane. C3a 
and C5a are also anaphylatoxins that promote inflammation  (Merle et al., 2019).   
Figure 4 illustrates in greater detail how free heme released during intravascular 
hemolysis activates the alternative complement pathway. Heme promotes the transition 
of C3 into C3(H20) and the formation of fluid phase C3 convertase. This leads to C3b 
deposition on RBCs and their subsequent lysis. The complement cascade is further 
activated by amplification loop that creates more C3b, C3a, and C5b-9 (Merle et al., 
2019) .  
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Figure 4. Free heme activates the alternate complement pathway. Figure taken from 
(Merle et al., 2019) 
 
 
Hemolytic Parameters  
 
 Several hemolytic parameters are used in the differential diagnosis and 
management of hemolytic anemia. These parameters are described briefly below. The 
normal clinical values of each parameter are listed in Table 2 (Barcellini & Fattizzo, 
2015).  
1. Hb is the most direct indicator of hemolysis. Mild forms of hemolysis can be 
close to normal Hb values (>10 g/dL) while severe forms are close to 6 g/dL. 
2. Reticulocytes indicate bone marrow erythropoietic activity because they are non-
nucleated precursors of RBCs. Reticulocyte count usually increases following 
hemolysis. However, an initial fall and rise in absolute reticulocyte count during 
recovery is common during hemolysis associated with DHTR (Win et al., 2010) 
3. Lactate dehydrogenase (LDH) is an enzyme responsible for the conversion of 
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lactate into pyruvate. LDH-1 and LDH-2 isoenzymes are expressed specifically in 
RBCs. Following hemolysis, LDH levels usually increase and can be used to 
distinguish between intravascular versus extravascular hemolysis.  
4. Haptoglobin, as described previously, is a glycoprotein with the ability to bind to 
free Hb to reduce the formation of reactive oxygen species and renal damage. The 
resulting hemoglobin-haptoglobin complexes are cleared by scavenger endothelial 
cells. Haptoglobin decrease following hemolysis.  
5. Bilirubin is made following the catabolism of the protoporphyrin IX ring of heme. 
An increase in bilirubin levels may be due to increased Hb catabolism or 
decreased hepatic clearance. Following hemolysis, hyperbilirubinemia is usually 
indicated by no more than 4mg/dL.  Higher values may indicate liver 
complications.  
6. Ferritin is an intracellular protein that stores and releases iron to buffer iron 
deficiency and overload. It can be used to indicate the total amount of iron in a 
body and generally increases following hemolysis.  
Table 2. Normal range of hemolytic parameters. M indicates male, F indicates female  
 
 Normal levels  
Hemoglobin  >10 g/dL  
Reticulocytes  20 × 109/L - 100 × 109/L 
Lactate Dehydrogenase (LDH)  240 - 460 U/L 
Haptoglobin  41-165 mg/dL  
Bilirubin  0.2 to .8 mg/dL  
Ferritin  12 -300 ng/mL (M) 12-150 ng/mL (F)  
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Frequency and Diagnosis of DHTR  
 DHTR is under-reported as its clinical presentations resemble those of VOC 
(Fabron et al., 1999).  In a retrospective study of chronically transfused SCD patients, 
DHTR, as evidenced by antibody detection, occurred in 30% of the cases (total 178). 
However, 39% of these cases were reported to blood banks as possible DHTR. 21 cases 
were identified as severe DTHR. (Coleman et al., 2019).  DHTR mortality can be as high 
as 11.5% (Narbey et al., 2017) 
There are no current diagnostic guidelines and consensus definition of this 
condition. Pirenne and Yazdanbakhsh proposed a two-step diagnosis of DHTR, based on 
clinical symptoms and levels of hemoglobin A (HbA) (Figure 5). The first step is based 
on vaso-occlusive symptoms (dark urine, onset, or worsening of anemia symptoms) and 
increasing LDH within three weeks of transfusion. This first step can indicate that DHTR 
is likely, allowing the physician to stop further transfusions. In the second step, DHTR is 
confirmed by a decrease in concentration and percentage of HbA relative to immediate 
post-transfusion levels. As SCD patients produce HbS and receive HbA from donor 
blood, lowered HbA levels signifies both the patient and donor RBCs are destroyed. The 
relative change in HbA concentration and days elapsed can be then used to indicate 
DHTR likelihood (Pirenne & Yazdanbakhsh, 2018).   
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Figure 5. Diagnostic guidelines for DHTR in adult SCD patients. The assessment 
criteria are based on clinical and laboratory presentations, including pain, anemia, urine 
color, elevated LDH.  Figure take from (Pirenne & Yazdanbakhsh, 2018) 
 
 
As mentioned previously, a key challenge is the under-recognized incidence of 
DHTR, as its clinic manifestation mimics VOCs. Gardner et al. (2015) highlighted some 
of the key differences between the two (Table 3). It is important to note that a negative 
direct antiglobulin test (DAT) does not exclude DHTR.  
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Table 3. Differentiating DHTR from VOC episodes. Table adapted from (Gardner et 
al., 2015) 
 
 DHTR  VOC episodes  
Context  Recent RBC transfusion (within 
2-21 days)  
Any  
Symptoms  Pain, fever, hemoglobinuria  Pain, fever  
Reticulocytes  Variable- relative 
reticulocytopenia or elevated  
Frequently elevated from 
baseline unless transient RBC 
aplasia from acute infection 
(e.g Parvovirus) 
LDH Highly elevated compared to 
baseline  
Mildly elevated compared to 
baseline  
Hb quantitation  Decrease in Hb to below post- 
or pre-transfusion level, rapid 
clearance of HbA% with 
concomitant increase in HbS%   
Unchanged or mild decrease 
from baseline; or if 
transfused, appropriate 
increase in Hb  
Immunohematology  DAT positive (~75%) or 
negative (~25%); new RBC 
alloantibody was detected in 
some cases  
DAT negative  
 
 22 
HOW CAN ALLOIMMUNIZATION BE PREVENTED? 
 
Antigen Matching  
In western countries, the standard of care for transfusing SCD patients include 
matching for Rh group (D, C, E, c, e) and K antigens (LaSalle‐Williams et al., 2011). 
However, there are no standard guidelines for antigen matching beyond these antigens to 
prevent alloimmunization. Moreover,  it is not clear which patients are likely to become 
alloimmunized (Yazdanbakhsh et al., 2012). Some transfusion services only provide 
antigen matched blood once alloantibody is detected in the patient. While some services 
offer extensive matching, other services only match for the most frequently immunogenic 
antigens (C, E, K) (Kacker et al., 2014). A multicenter study using a pediatric cohort 
showed alloimmunization rate dropped from 3% to 0.5% when matching for E, C, and K 
(Vichinsky et al., 2001).  
While it is certain that antigen matching should be prioritized to prevent 
alloimmunization, this is no consensus on which antigens should be matched. 
Yazdanbaskhsh recommends SCD patients to avoid exposure to highly immunological 
antigens (RH, KEL). For patients that are already immunized, less immunogenic blood 
groups (FY, JK, MNS) should be avoided.  
La Salle-William et al. (2011) reviewed records for 99 SCD patients in a 
prophylactic extended matching program at the Colorado Sickle Cell Treatment and 
Research Center from the period 1993 to 2006. While most patients have homozygous 
SCD (HbSS), 14% had HbSC or HbS beta-thalassemia. The study population received 
transfusions from infancy to adulthood, with a mean range of 5 months to 19 years. 
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Patients and donors were phenotyped for 20 blood groups, including ABO, RH, KEL, 
FY, JK, Lewis, and MNS. While attempts to match each negative antigen in the recipient 
and donor were made for each transfusion request, a perfect match was not always 
possible. Mismatches were allowed for MNSs, Fyb, and Lewis due to the lower 
immunogenicity of these antigens. When these mismatches were allowed, 90% of 
transfused units were perfectly matched (LaSalle‐Williams et al., 2011). 
Table 4 below describes the results of this extended antigen matching program 
along with other patient cohorts for a wider variety of indications since 1993. 
Alloimmunization, along with antibodies per 100 unit transfused, decreased with 
extended matching. Note that  extended matching beyond ABO and D can significantly 
reduce the percentage of patients immunized (LaSalle‐Williams et al., 2011).  
 
Table 4. Alloimmunization in patients treated with extended matching protocol. 
Patients were in each group were analyzed separately. *Different from historical value, p 
< 0.00005. Table adapted from (LaSalle‐Williams et al., 2011) 
 
Patient Group  Matching  Percentage of 
Patients 
Immunized  
Rate 
(antibodies/100 
units 
transfused)  
Chronic Transfusion 
n=85  
ABO, D  34% 3.4 
Chronic Transfusion 
n=12  
Extended matching 
for all who had 
previously 
received ABO, D  
25%  0.3 
Chronic Transfusion 
n=13  
Extended matching  8%* 0.08* 
Chronic and Intermittent 
 n=99  
Extended matching  7%  0.10 
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Another factor to consider is the cost-effectiveness of prospective extended 
antigen matching programs. The cost of medical care for one SCD patient over a lifetime 
is greater than $460,000 (Kauf et al., 2009), while an estimated 700,000 to 100,000 
people suffer from SCD (Hassell, 2010). Kacker et al. (2014) constructed a stimulation 
model (Markov-base model) to compare the health and financial implication for four 
different antigen-matching strategies for SCD patients over 10 and 20 year periods. The 
four strategies differed by the extent of antigen matching (C, E, K or C, c, E, e, K, Fya, 
Fyb, Jka, Jkb, S, s). The results showed over 10 years, prospective extended matching 
would cost $1.8 billion more than history-based extensive matching while avoiding 2424 
alloimmunization events. In order to prevent a single alloimmunization event, the cost 
would be between $369,482 to $769,284 (Kacker et al., 2014).  
 
Increasing RBC donations from persons of African descent  
  One barrier in treating SCD patients is the lack of blood donations from minority 
groups. In the US, blood donation rates from AAs are significantly lower compared with 
whites. In 2019, a cross-sectional analysis was performed among 28, 739 participants in 
the 2016 National Health Interview Survey (NHIS). The NHIS is a household survey for 
noninstitutionalized US civilian population at both national- and census- region level. 
The sample includes people over 18 years old living in households and non-institutional 
group quarters (e.g., college) throughout the US. The survey was conducted in person by 
trained interviewers. The outcome of interest was determined by asking the question,  
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“During the past 12 months, have you donated blood?” Participants who answer “yes” 
were considered past year donors (Patel et al., 2019). 
 The prevalence of blood donations in the past 12 months stratified by age and 
race/ethnicity is shown in Figure 6. In this study, young adults were more likely to 
donate blood than older population. Across all age categories, a past-year history of blood 
donation was more common in males (6.3%) compared to females (5.1%). Across all age 
categories, a past-year history of blood donation was lower in AAs (3.9%) and Hispanics 
(3.0%) compared to whites (6.9%). Furthermore, being a college graduate, employed, 
physically active, and non-smoking positively correlated with donating blood. Lastly, the 
prevalence of blood donation was higher in the Midwest (7.4 %) and South (6%) 
compared with Northeast (4.7%) and West (4.4%) (Patel et al., 2019).   
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Figure 6. Age-specific self-reported prevalence of blood donation in the past 12 
months. The data stratified by age (A) and ethnicity (B). “Other” consist of non-Hispanic 
Asian, Hispanics, and non-Hispanic other/multiracial groups. Data were weighted, and 
error bars reflect design-adjusted, logit-transformed 95% confidence intervals. Figures 
taken from (Patel et al., 2019).  
 
 
 
The above results are consistent with a 2017 study that evaluated the changes in 
minority blood donation over a period from 2006 to 2015. Data from RBC donors were 
collected annually by eight large blood collectors in the United States. The results show 
that white donors donated the highest proportion of RBC units (76.3% - 80.2%) and 
constituted the majority of donors (76.1%- 79.8%). During the 10 year study period, AA 
donors contributed 4.0% to 4.3% of all donated RBC units and constituted 4.95% to 5.2% 
of all donors. Lastly, linear regression of the data showed a decreasing trend in the 
number of donors, collection, and RBC units over the study period (Yazer et al., 2017).  
  In 2019, Spratling et al. (2019) conducted a meta-synthesis review using various 
electronic databases to determine the facilitators and barriers for blood donation. Three 
common themes were determined (1) knowing a blood recipient, (2) identifying with 
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culture, race/ethnicity, and religious affiliation, (3) medical mistrust and 
misunderstanding. The themes are further described using examples in Table 5 below. 
(Spratling & Lawrence, 2019).   
Table 5. Facilitators and barriers to blood donation in minority communities. Table 
adapted from (Spratling & Lawrence, 2019). 
 
Themes  Summary  Example 
Knowing a blood 
recipient  
Knowing a blood recipient (friend, 
direct or indirect family member) 
made a minority donor more likely 
to donate  
When asked about emotions 
associated with donating 
blood, AA donors reported 
“hearing people’s personal 
stories is inspiring” and 
“something happens to 
someone in my family” 
(Amoyal et al., 2013).  
Identifying with 
culture, 
race/ethnicity, 
and religious 
affiliation  
Identifying culture, race/ethnicity, 
and religion provide a reason for 
some minority donors to donate  
AA donors expressed blood 
donating would benefit their 
own community (Mathew et 
al., 2007) 
Perceived social exclusion 
was reported to be a 
fundamental issue for AA 
donors (Tran et al, 2013) 
Medical mistrust 
and 
misunderstanding  
Unclear explanation for donor 
deferrals and suspicion about 
blood donation are barriers to 
donation  
AA donors reported feeling 
their blood was unwanted or 
their donation would be later 
discarded (Tran et al., 2013) 
 
 
New York Blood Center (NYBC) is a nonprofit blood distribution organization 
that collects and processes 400,000 units of blood annually for 200 metropolitan-area 
hospitals. In 2005, the New York Blood center developed and implemented the 
PreciseMatch program to increase blood donations from AA or black and Hispanic or 
Latino donors to increase the chance that alloimmunized patients will receive properly 
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matched blood. The goal of the PreciseMatch program was to increase donations among 
AA and Hispanic/Latino donors by 150 incremental units per month (Frye et al., 2014).  
PreciseMatch Program is a community-oriented education program that relied 
heavily on one-on-one outreach. Professional outreach coordinators (1) provided 
education in target communities to address myths and misconceptions about blood 
collection; (2) promoted awareness for the need of blood donations among AA or black, 
Hispanic or Latina, and other ethnically diverse communities; (3) built relationships with 
communities and their leaders. The coordinators focused their outreach at churches, 
community centers, health expos, parades, and street fairs in Manhattan, Bronx, and 
Brooklyn. The marketing materials used included formal presentations, posters, and 
brochures in both English and Spanish. The brochures featured three local Latino SCD 
patients’ stories. NYBC’s communication and Media Relations department also played a 
significant role in bringing attention to the program. Information regarding various events 
and blood drives were covered in all local Spanish language newspapers and radio 
stations with sizable AA or black audiences. A systematic analysis of program 
documentation and collection data revealed that PreciseMatch achieved 75% of the  
original goal, with 75% of donors being first time donors (Frye et al., 2014).  
 
Rituximab  
Rituximab is a chimeric monoclonal antibody against CD20, a protein found on 
the surface of B cells. Figure 7 illustrates the three main pathways that rituximab 
depletes B cells: (1) antibody dependent cellular cytotoxicity (ADCC), (2) complement 
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medicated cytotoxicity and (3) apoptosis (Seyfizadeh et al., 2016). Rituximab is used 
generally used to certain cancers such as Non-Hodgkin’s lymphoma and chronic 
lymphocytic leukemia. B cell depletion using rituximab is also known to be effective 
against a variety of autoimmune diseases including autoantibody-mediated hemolytic 
anemia (Pirenne et al., 2015; Bachmeyer et al. 2010). 
 
 
 
Figure 7. Mechanisms of action of rituximab to deplete B cells. Figure taken from 
(Seyfizadeh et al., 2016)  
 
Several case studies have documented positive outcomes with rituximab in DHTR 
patients. Noizat-Pirenne et al. (2015) conducted a single-center observational study on 
eight SCD patients following rituximab administration and transfusion. All eight patients 
had a definitive diagnosis of SCD and a prior history of DHTR (one did not have a prior 
history but was alloimmunized). Rituximab was administered before transfusions to 
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prevent further immunization and DHTR. 10 mg of methylprednisolone (MP) was 
administered before rituximab in all cases. 
 All patients received units that were matched for Rh, KEL, FY, JK, and MSN 
blood groups. Following transfusion, five patients showed good clinical outcome defined 
by the lack of post transfusion VOC, lack of hemoglobinuria, and HbA that persisted 
within 1 month most post transfusion. The remaining three patients presented mild 
DHTR defined by a rapid decrease of HbA and total Hb within 5 to 15 days post 
transfusion. One patient also presented with mild vaso-occlusive complications. Lastly, 
the results of post transfusion and pre transfusion screening test exactly matched in all 
eight patients, indicating that no new antibodies were detected (Noizat-Pirenne et al., 
2015).  
Pirenne et al. (2015) demonstrated that rituximab could prevent the formation of 
new antibodies and minimize the risk of severe DHTR. In cases when a patient with prior 
DHTR history and needs additional transfusions, rituximab can be considered. However, 
long term usage of rituximab should be evaluated as chronic B cell depletion can increase 
the risk of infection, especially those with functional asplenia. The patient should be 
vaccinated against pneumonia at least two weeks before using rituximab. Furthermore, 
the three patients who still developed mild DHTR in the absence of newly antibodies 
suggest that DHTR depends on other complex heterogeneous mechanisms in addition to 
the classical antibody-mediated responses (Pirenne et al., 2015).  
Nickel at al reported a case where the use of prophylactic rituximab in a SCD 
patient with previous DHTR history had a fatal outcome. The patient (19 yo, male) 
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desired a hip replacement surgery due to daily pain and ambulatory difficulties. He 
previously suffered three DHTRs, hyper-hemolysis, and had a history of multiple RBC 
alloantibodies (anti-C, -E, -K, -Fya, -Fyb, -Jkb, and -M) and autoantibodies. Despite using 
rituximab preemptively to prevent DHTR, the patient still suffered from severe DHTR, 
hyper-hemolysis, and Salmonella sepsis 3 days post transfusion. The patient passed away 
three days later (Nickel et al., 2016).  
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HOW IS DHTR CURRENTLY TREATED? 
Corticosteroids  
High dosage corticosteroids have been used as the first line of defense for severe 
DHTR cases, commonly with intravenous immunoglobins (IVIg) (Vidler et al., 2015). 
Corticosteroids are known to improve antibody-mediated hemolysis, pain episodes, acute 
chest syndrome, and other steroid-responsive conditions. However, studies indicate that 
corticosteroids are associated with severe vaso-occlusive complications. Darbari et al. 
(2008) reported four SCD patients with vaso-occlusive events after administration of 
systemic steroid therapy. Other similar cases were also reviewed from literature to 
determine the potential risks associated with systemic corticosteroids. Some of the 
adverse health effects are present below in Table 6 (Darbari et al., 2008).  
 
Table 6. Adverse health effects of steroids use in SCD patients. Table adapted from 
(Darbari et al., 2008). ACS = acute chest syndrome. VOC = vaso-occlusive crisis   
 
Age of 
Patient  
Time to 
Adverse 
outcome  
Complications  Author’s 
Conclusion  
Citation  
21 Few days  Pain crisis, mental 
confusion, cardio-
respiratory arrest 
followed by death; 
evidence of bone 
marrow necrosis and fat 
embolization on 
autopsy  
Elevated level 
of IgG and 
treatment with 
corticosteroids 
appeared to a 
major factor in 
the death   
(Shapiro & 
Hayes, 1984) 
25 3 days  Pain crisis, respiratory 
arrest, followed by 
death; evidence of fat 
embolism, bone marrow 
necrosis on autopsy   
 (Johnson, 
Stastny, & 
Rucknagel, 
1994) 
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3-18  Within 14 
days  
Hemorrhagic stroke (9) Primary 
hemorrhage in 
children with 
SCD is 
associate with 
recent 
transfusion of 
corticosteroid  
(Strouse et al, 
2006) 
7- 46  3-45 days  Bone marrow infarction 
(3), fat embolism (1), 
ACS (3), VOC (3), 
priapism(1), 
neurological symptoms 
(1)  
Use of system 
steroid can 
precipitate 
severe vaso-
occlusive 
episodes in 
SCD patients  
(Darbari et al., 
2008) 
 
 
Darbari et al.  (2008) suggest a causative role of corticosteroids in the presented 
detrimental health events due to three main observations: (1) health events followed 
corticosteroid administration, (2) vaso-occlusive episodes become more severe compared 
with pre-corticosteroid clinical course, (3) detrimental health events reoccurred in some 
patients following re-initiation of systemic corticosteroid therapy (Darbari et al., 2008). 
Although the exact mechanism of how corticosteroids induce vaso-inclusion is unclear, it 
should be used minimally, especially in children. Elenga et al. (2008) reported two 
children presenting with severe neurological complications in children after receiving 
corticosteroid therapy. Garden et al. (2015) recommends 2 mg/kg/day of MP with a 
maximum dosage of 60 mg/d along with a slow tapering period in children (Elenga et al., 
2008; Gardener et al., 2015).  
 
Intravenous Immunoglobin  
 
Immunoglobulin therapy is used to treat a variety of health conditions, and its 
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usage is expanding in autoimmune diseases (Katz et al., 2007). IVIg is frequently used to 
treat DHTR even in cases where no antibodies were detected (Pirenne & Yazdan bakhsh, 
2018). In a retrospective case review in France, Montalembert et al. (2011) studied eight 
pediatric SCD patients that developed DHTR for the period 2006 to 2009. Four patients 
that received IVIg therapy (1-4 injections, 0.5 -1 g/kg) showed success in infusion 
tolerance and resolution of the hemolytic process. Two patients without detectable 
antibodies were also treated successfully with IVIg. Pirenne and Yazdanbaksh 
recommend IVIg as the first line of defense for DHTR patients with post transfusion 
hemolysis regardless of antibody detection, because antibodies can be formed at a later 
point (Pirenne & Yazdanbakhsh, 2018).  
A case study published by Win et al. (2010) further supports the use of IVIg 
therapy. A patient (35 yo, female) presented with severe DHTR and a previous history of 
alloantibodies against S, Fy3, and Jkb (Figure 8). Two days following admission, the 
patient’s Hb dropped to 47g/L. The patient was administered IVIg (0.4 g/kg) for 5 days 
and MP (500mg/d) for 2 days. The patient’s Hb level, absolute reticulocyte count, 
bilirubin, and LDH level is shown below with the administration of IVIg and MP. The 
patient was discharged 11 days later with Hb level of 65 g/L.  Furthermore, Win et al. 
(2010) identified five more patient cases where anemia and hemolysis were resolved 
using IVIg and MP in the absence of additional transfusions (Win et al., 2010) .  
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Figure 8. Hb concentration, absolute reticulocyte count, bilirubin, and LDH after 
treatment with IVIg and methylprednisolone.  Arrows indicate when IVIg or MP were 
administered. Figure taken from (Win et al., 2010).  
 
 
The mechanism of action of IVIg in alleviating DHTR symptoms remains 
unclear. IVIg therapy may act by inhibiting the cellular immune response associated with 
SCD (Montalembert et al., 2011). For example, IVIg can inhibit inflammation and 
macrophages by inducing the production of interleukin-1 receptor antagonist (Crow et al., 
2007). Also, in SCD mouse models, it was demonstrated that IVIg inhibited neutrophil 
adhesion to reverse vaso-occlusive crisis (Chang et al., 2008).  
In a literature review with over 200 patients receiving IVIg for different 
autoimmune diseases, 24% to 36% reported adverse effects after a high dosage. The 
majority of these events were immediate and mild. These included headaches, face 
flushing, malaise, fever, chills, fatigue, dyspnea, nausea, vomiting, diarrhea, changes in 
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blood pressure, and tachycardia. Later adverse health events tend to be more serious. 
These include acute renal failure, thromboembolic events, skin reactions, and 
autoimmune hemolytic anemia. However, the authors concluded that IVIg is a safe 
therapy to use if infused slowly in well hydrated patients and avoiding patients with 
known risk factors (Katz et al., 2007).  
 
Eculizumab  
 Eculizumab is a monoclonal antibody that inhibits C5 convertase by preventing 
the cleavage of C5 into C5a and C5b (Pirenne et al., 2017). By stopping the complement 
cascade at this stage, terminal complement activation is inhibited. Eculizumab is used to 
treat atypical uremic syndrome and paroxysmal nocturnal hemoglobinuria (PNH). 
Eculizumab decreases the destruction of RBCs and increases transfusion independence in 
PNH patients (Martí‐Carvajal et al., 2014). 
 The efficacy of eculizumab in treating DHTR was analyzed in a case series by 
Dumas et al. (2016) at the French Sickle Cell Referral Center. This study reported data 
from 3 homozygous SCD patients hospitalized for DHTR with hyper-hemolysis. All 
three patients presented without detectable antibodies following transfusion. Two fixed 
doses of eculizumab (900 mg) were administered to each patient one week apart as 
salvage therapy. In addition, plasma was collected and frozen from each patient to 
characterize complement activity. Figure 9 illustrates the event story and treatment for 
all three patients (Dumas et al., 2016).  
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 Patient 1 (20 yo, female) presented with severe acute VOC 6 days post transfusion 
(Figure 9A). The transfused units were matched with Rh, Jell, Fy, and MNS blood 
groups due to a previous history of anti-S antibody production. DHTR was diagnosed 
based on the decreases in Hb and HbA. After the first day of eculizumab administration 
along with erythropoietin (EPO), the patient’s bone pain disappeared and her urine 
became yellow. Hemolysis, as indicated by haptoglobin and bilirubin levels, gradually 
decreased while Hb levels increased. The patient was discharged on day 18. (Dumas et 
al., 2016).  
Patient 2 (17 yo, female) presented with severe acute chest syndrome, fever, and 
dark-color urine 7 days post transfusion (Figure 9B). Because the patient had severe 
anemia and acute kidney injury, two units of RBC cross-matched for Kell and Rh was 
given to the patient. The patient’s clinical conditional deteriorated quickly, with acute 
hemolysis, respiratory, liver, cardiac, and kidney failure. Transfusion was immediately 
stopped, and plasma exchange was administered along with eculizumab and EPO. 
Gradually, intravascular hemolysis, kidney, respiratory, cardiac, and liver abnormalities 
were all resolved. Hb levels also increased, and the patient was discharged on day 
48 (Dumas et al., 2016).  
 Patient 3 (18 yo, male) presented with VOC and dark-colored urine 7 days post 
transfusion (Table 9C). He received units that were matched for D, C, E, and Kell. On 
day 9, the patient’s condition deteriorated with shock, acute liver failure, kidney injury, 
and increase in hemolytic parameters. Eculizumab, broad-spectrum antibiotics, platelet, 
and plasma transfusions were administered. On day 13, the patient received a liver 
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transplant. Due to this major surgery and the large number of blood units needed, the 
patient received a total of 59 RBC units matched only for Rh and Kell during day 8 to 22. 
The patient's haptoglobin level increased to 0.42g/L on day 10, indicating the 
disappearance of hemolysis. Unfortunately, the patient died on day 23 from a severe 
pulmonary infection (Dumas et al., 2016).  
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Figure 9. Hb, HbA, reticulocytes, and LDH after treatment of eculizumab. Time 
history of  patient 1 (A), patient 2 (B), patient 3(C).  Day 0 indicates the day of the 
transfusion responsible for the hemolytic episode. Blue arrows represent eculizumab 
infusion. Black arrows indicate EPO injection. Red arrows indicate RBC transfusion 
days. Green arrows represent plasma exchange sessions. HbA is indicated as a percentage 
of total Hb concentration. Figure taken from (Dumas et al., 2016) 
 
 
 Table 7 summarizes the complement data before and after eculizumab 
administration.  The high level of soluble terminal protein complex (sC5B9) indicates 
MAC formation and terminal complement activation occurred in all three patients. Table 
8 summarizes the normal values of C3, C4 and sC5B9  (Dumas et al., 2016). 
 
Table 7. Complement Analysis Before and After Eculizumab Infusion. Data is in 
mg/L *Day after first eculizumab injection. Table adapted from (Dumas et al., 2016)  
 
 Day*  C3 level  C4 level  sC5B9 level  
Patient 1      
Before eculizumab infusion  0 1080 266 856 
1st follow up  12 1030 283 1233 
2nd follow up  14 1050 248 1406 
Patient 2      
Before eculizumab infusion  0 - - - 
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1st follow up  7 1270 257 1797 
Patient 3      
Before eculizumab infusion  0 1070 220 1527 
1st follow up  4 313 104 296 
2nd follow up  6 359 129 224 
3rd follow up  9 928 526 355 
4th follow up  13 1210  290 509 
 
Table 8. Normal Values of C3, C4, and sC5B9. Table adapted from (Dumas et al., 
2016) 
 
C3  660-1250 mg/L 
C4  93-380 mg/L  
sC5B9  <450 ng/mL 
 
These data exemplify the potential severity of DHTR with hyper-hemolysis. 
Dumas et al. (2016) suggest that eculizumab should be administered at the first sign of 
DHTR. However, using eculizumab carries the risk of infection with encapsulated 
organisms, such as meningococcal disease. Meningococcal vaccination is recommended 
at least two weeks before receiving eculizumab (Benamu & Montoya, 2016). In 2017, the 
CDC released a report indicating that there were 16 cases of meningococcal disease in 
eculizumab recipients from 2008 to 2016. The majority of these cases occurred in 
recipients with at least one dose of meningococcal vaccine before disease onset, 
indicating that prophylactic vaccination can-not be expected to prevent all cases of 
infection (McNamara, 2017). 
 
Tocilizumab  
Tocilizumab is a monoclonal antibody against the interleukin-6 receptor (IL-6). It 
is commonly used to treat rheumatoid arthritis, systemic juvenile idiopathic arthritis, 
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giant cell arteritis, and macrophage activation syndrome (Sivapalaratnam et al., 2019). 
IL-6 is an inflammatory cytokine that also induces B cell and T helper cell 
differentiation. When secreted by neutrophils and macrophages, IL-6 induces endothelial 
cells that release chemokines to recruit more immune cells and acute-phase proteins. 
When tocilizumab binds to IL-6R, the pro-inflammatory functions of IL-6 are inhibited 
(Sheppard et al., 2017).  
Sivapalaratnam et al. (2019) reported successful treatment using tocilizumab in a 
SCD patient suffering from DHTR with hemolysis. The patient (33 yo, male) presented 
with pain crisis, respiratory failure, and ACS with a previous history of DHTRs (Figure 
10). He was immediately given an emergency automated red cell exchange transfusion 
(ARCET), treated with IVIg (0.4 g/kg/day) for 5 days, and MP (500 mg) for 3 days. 
Despite this, his Hb dropped sharply while hemolytic markers (LDH, bilirubin, ferritin) 
increased. He was treated with tocilizumab (8 mg/kg) intravenously for two days. Two 
days after tocilizumab treatment, the patient's urine cleared, reticulocyte increased, and 
hemolytic markers improved. Alloantibodies and autoantibodies were not detected in his 
serum screening. The patient tolerated tocilizumab well as no adverse effects were 
reported (Sivapalaratnam et al., 2019). Lee et al. (2019) reported a similar case where 
tocilizumab along with hemoglobin-based oxygen carrier-201 (a bovine based blood 
substitute) drastically resolved hemolysis in a SCD patient (Lee et al., 2019). 
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Figure 10. Serum ferritin, LDH, bilirubin, and reticulocyte count after two doses of 
tocilizumab. Black arrows indicate tocilizumab administration. Figure taken from 
(Sivapalaratnam et al., 2019).    
 
 
The most common adverse effects associated with tocilizumab in rheumatoid 
arthritis patients are upper respiratory tract and gastrointestinal disorders. Respiratory 
tract infections include the common cold, pneumonia, and staphylococcus cellulitis. 
Gastrointestinal disorders include abdominal pain, mouth ulceration, and gastritis 
(Sheppard et al., 2017).   
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An alternative to transfusion and immunosuppresants: Hematopoietic Stem Cell 
Transplantation  
An alternative to transfusion therapy for SCD patients is hematopoietic stem cell 
transplantation (HSCT). Despite HSCT being a curative therapy, its use remains limited 
due to lack of donor options, perceived mortality in procedures, referral bias, provider 
preference, poor education and families, and costs.  While both the long-term and 
disease-free survival exceed 90% for matched sibling donor HSCT in children, the 
impact on adults remains largely unknown. In addition to the limited number of clinical 
trials in adult SCD patients, there is a general lack of consideration and popularity for 
HSCT as therapy for adults (Aslam et al., 2018).  
The under-utilization of HSCT can be partly explained by the lack of donor 
availability. When patients do not have a suitable related HLA-matched donor, other 
potential sources of donors include adult volunteers and banked umbilical cord blood 
units. Using human HLA data from the National Marrow Donor Program and cord-
blood-unit registry, Gragert et al. (2014) built population based genetic models to predict 
the likelihood of finding a suitable donor in the US registry for 21 US racial and ethnic 
groups. Their data suggested that most HSCT candidates will find a suitable adult donor 
(HLA- matched or minimally mismatched). However, many patients will not find an 
optimal adult donor that is matched at high resolution at HLA-A, HLA-B, HLA-C, and 
HLA-DRB1. The likelihood of finding an adult donor also varies within racial and ethnic 
groups, with White Europeans having the highest probability (75%) and AA (19%), 
Black (18%), South or Central American (16%), Black Caribbean (19%) having the 
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lowest (Gragert et al., 2014).  Other studies have reported that only 14%-35% of SCD 
patients have an HLA-matched related sibling (Stallings et al., 2019). 
 Interestingly, sociocultural factors in both patients and providers may also 
contribute to the under-utilization of HSCT in both adults and children (Bakshi et al., 
2017). Stallings et al. (2019) used a nation-wide web-based survey of pediatric 
hematologists/oncologists to identify the clinical attitudes surrounding HSCT. The 37 
question survey was conducted for the period February to May 2016 and distributed to 70 
pediatric hematology/oncology fellowship programs across the US. Survey responses 
were analyzed using multivariable linear regression to determine the relationship between 
clinician attitude and practice of discussing this therapy with SCD patient families (Table 
9) (Stallings et al., 2019).  
 
 
Table 9. Clinician attitudes about hematopoietic stem cell transport as therapy for 
SCD in children. Graft versus host disease (GVHD). Table adapted from (Stallings et 
al., 2019). 
 
 Percentage  95% CI  
Adequacy of evidence and comfort discussing HSCT    
Reported that they felt comfortable disccusing HSCT 92% 88‐95 
 
Believed there is adequate evidance to support HSCT  93% 90-96  
Saftey and Efficacy of HSCT    
The mortality rate after HSCT is too high to justify its use 
in most children with SCD  
69% 
disagreed  
63–74 
The rate of cure after HSCT is too low to justify its use in 
most children with SCD 
77% 
disagreed  
71-81  
The risk of GVHD* after HSCT is too high to justify its use 
in most children with SCD  
70% 
disagreed  
64-75  
Perception about the cost of HCT    
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The cost of HSCT to the family is too high to justify its use 
in most children with SCD 
12 % agreed  9-16  
The cost of HSCT to the system is too high to justify its use 
in most children with SCD  
11% agreed  8-15  
 
 
Figure 11 and 12 below illustrates the relationship of clinician attitudes and the 
timing of discussing of HSCT with patient families. Clinicians with more negative views 
about the safety and efficacy of HSCT were more like to discuss HSCT after the patient 
passes a certain threshold of disease. Similarly, clinicians who reported high costs were 
more likely to discuss HSCT after the patient passes a certain threshold of disease 
(Stallings et al., 2019).  
In 2014, an international consensus recommended all SCD patients with 
symptomatic disease and an available donor undergo HSCT as soon as possible. 
However, the results of this study reported nearly half of clinicians used their own 
perspectives about what constitutes  “diseases severity” to guide their timing of 
discussing HSCT (Stallings et al., 2019).  
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Figure 11.  Relationship between clinician attitudes about GVHD and timing of 
discussing HSCT with patient families. Figure taken from (Stallings et al., 2019). 
 
 
Figure 12. Relationship between clinician attitudes about the cost of HSCT and 
timing of discussing HSCT with patient families. Figure take from (Stallings et al., 
2019).  
  
Lastly, approximately two-thirds of providers reported treatment adherence as a 
decision factor in informing a family about HSCT (Stallings et al., 2019). Low 
socioeconomic status (SES) patients/families have many barriers to treatment adherence, 
including, low health literacy, housing or food insecurity, and difficulty in securing 
transportation.  Adherence to HSCT therapy may be especially challenging to low SES 
patients/families as it requires a multitude of appointments, tests, imaging, and 
vaccinations (Walsh et al., 2014).   
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EVALUATION OF METHODS   
 
Current projections predict that the number of newborn babies with SCD will 
exceed 400,000 by 2050 (Aslam et al., 2018). While transfusions remain the cornerstone 
of SCD therapy, frequently transfused patients are at risk of alloimmunization, DHTR, 
and resulting life-threatening complications. In this section, the current methods in 
preventing alloimmunization and treating DHTR are evaluated to identify gaps of 
knowledge and future directions. 
 
Antigen matching to reduce alloimmunization  
LaSalle- William et al. (2011) showed the effectiveness of prophylactic matching 
for Rh, KEL, FY, JK, MSN antigens.  SCD patients typically have the phenotype D+C-E-
C+e . To avoid alloimmunization against C and E, SCD patients are typically given units 
with the same phenotype, which is found in less than 2% of white donors. The alternative 
is to use units with D-C-E-C+e+ phenotype, which will deplete the already limited D- 
units. However, white donors who are D- typically express other immunogenic antigens 
(Fya, Jkb, S).  The use of D- units from white donors can thus expose black recipients to 
these antigens that lead to alloimmunization (Yazdanbakhsh et al., 2012).  
 Moreover, prospective matching does not benefit every patient as Rh-compatible 
units do not totally prevent alloimmunization due to numerous Rh variants that exist in 
SCD patients (Table 1). Lastly, the mechanism of action for antibody negative DHTR is 
still unknown. It is possible that DHTR may act through a non-antibody mediated 
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pathway. In combination with its high cost (Kacker et al., 2014) prospective matching for 
all transfused patients may not be an optimal strategy.   
 
Increasing blood donations from African Americans and other minorities   
 Strategies to increase RBC donations from AA and other minorities can 
significantly increase RBC shortage for SCD patients and decrease alloimmunization. 
The distribution of blood donors remains mostly unchanged over the past 10 years, with 
continued under-representation of AA, Hispanic, and Asian donors. Sprawling and 
Lawrence identified knowing a blood recipient, identifying with a culture, race/ethnicity, 
and religious affiliations as facilitators for blood donation. Sprawling, Lawrence, and 
Lyre at al all identified medical mistrust as the primary barrier in blood donations. There 
is clear support that strategies should focus on building rapport and establishing good 
relations, as social, cultural identity, and trust play a significant role in blood donations 
among minority groups.   
The PreciseMatch is one example of a successful program to increase blood 
donation from minority groups. However, the program was difficult to implement as it 
takes a considerable amount of time to establish good relationship with the relevant 
population. The activities to build rapport and educate members took more time and 
energy than anticipated, resulting in fewer blood drives and blood collections. 
Maintaining drives and collections requires sustained manpower and financial support. 
Currently, the PreciseMatch program is not as robust due to market pressures and lack of 
funding (Frye et al., 2014).  
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One interesting challenge to highlight is the higher deferral rate in AA women 
(25%) compared with white women (75%), due to lower normal Hb concentration among 
AA women (Shaz et al., 2010).  Some AA women donors reported believing that deferral 
due to low Hb prevented them from ever donating blood (Frye et al., 2014).  
 Lastly, there is an additional concern with increasing RBCs units from AA 
donors. Up to 10% of AA will have the sickle cell trait (SCT) and carry one gene for 
sickle Hb. While people who carry SCT lead normal lives without any medical 
complications, it is not known whether transfusing SCD patients with SCT blood 
products will cause any adverse side effects. In the US, persons with SCT are eligible to 
donate blood. However, transfusion guidelines for SCD recommend the leukoreduction 
of RBC units by filtration. In many cases, blood from SCT donors do not filter 
adequately (Yazdanbakhsh et al., 2012).  
 
Immunosuppressants to treat DHTR    
 
The current treatment of DHTR is quite limited, with a focus on the five 
immunosuppressive agents listed so far this literature review. The various are 
summarized and compared in Table 10 below. The various agents are listed in decreasing 
documented usage, with tocilizumab being used the most recently as a treatment for 
DHTR.  
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Table 10. Summary of immunosuppressive drugs for DHTR.  
 
 Corticosteroid
s  
IVIg  Rituxima
b  
Eculizumab  Tocilizumab 
Mechanism of 
Action  
Unclear but 
possible  
suppression of  
macrophage 
activity  
Not 
completely 
understood   
Depletes 
B cells  
Inhibit 
terminal 
complemen
t pathway  
Inhibits IL-6R  
Adverse health 
effects  
VOC, 
hemorrhagic 
stroke, 
respiratory 
complications  
Typically 
mild, Severe 
effects include 
renal failure, 
hyperviscosity
, and 
hemolysis   
Increase 
risk of 
infection 
after 
chronic 
use  
Increased 
risk of 
infection 
after 
chronic use  
Upper 
respiratory 
tract and 
gastrointestina
l disorders, 
but not 
documented 
in DHTR 
patients  
Vaccination 
Recommended
?   
No  No  Yes  Yes  No  
Fatal outcome 
in DHTR  
Yes  Yes  Yes  Yes  No  
   
  IVIg and corticosteroids are currently the standards of care. However, there are no 
guidelines for using them as a first-line treatment. There are also no evidence-based 
studies to support the use of one over the other. The risks of VOE aggravation, 
hyperviscosity, and kidney toxicity associated with corticosteroid and IVIg usage are 
more severe compared to the side effects of rituximab, eculizumab, and tocilizumab. 
Their use should be carefully evaluated for each patient, especially in children.  
 While eculizumab and tocilizumab are used to treat DHRT, rituximab is used to 
prevent new antibody formation if the patient requires additional transfusions. Prolonged 
use of rituximab and eculizumab increases the risk of infections; their use should be 
carefully evaluated in immunocompromised SCD patients. The lack of adverse health 
effects in tocilizumab can be due to the small number of case studies documenting its 
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usage. Lastly, it is also important to take into consideration the cost of these drugs. 
Eculizumab is considered to be one of  the most expensive drug in the world, averaging 
about $18,000 per dose or approximately $500,000 annually (“Why is Soliris the Most 
Expensive Drug in the US?,” 2017).  
 The highlighted case studies in this review also demonstrate the potential 
complexity and severity in DHTR cases. The progression from mild to severe DHTR is 
largely unpredictable. In cases of severe DHTR, a patient’s immune activation and 
response to treatment may also differ. Additional mechanistic studies to understand the 
pathophysiology of alloimmunization and DHTR are essential to provide tailored 
treatment for SCD patients.   
 While HSTC is a viable alternative to transfusion therapy,  its utilization currently 
remains low in the US due to limited donors, perceived mortality in patients, and 
clinician attitudes. Stalling et al. (2019) demonstrated that pediatric 
hematologist/oncologists hesitate in discussing HSCT as a treatment option with patient 
families due to concerns with safety, efficacy, cost and treatment adherence.  
 
Sickle Cell Disease as a Social Disparity   
  This literature review has shown that treatment for DHTR in SCD is largely 
insufficient. There are currently no clinical trials or new drugs that specifically treat 
DHTR. The aforementioned immunosuppressants are drugs frequently used to treat other 
immune disorders. This review also found frequent recurrences of authors in this topic, 
suggesting that few studies are done on this much-needed area of research. Moreover, a 
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majority of the literature on SCD and DHTR is published in journals relating to 
transfusion and blood disorders. It is equally important that issues surrounding SCD and 
DHTR be analyzed from medical, public health, and health policy perspectives. 
 The low public interest and knowledge in SCD can also be attributed to structural 
violence. Structural violence refers to how society’s structure, systems, and policies 
unjustly affect the well-being of individuals. While the reasons for the absence of 
effective treatment options is multifactorial and difficult to pinpoint, some argue it is 
because such endeavors are not seen as financially or politically profitable (Shiffman, 
2006). Bhar and Song argue health disparities faced by SCD patient in the US are a result 
of economic and racially motivated factors that make up the rubric of structural violence 
(Bahr & Song, 2015).  
  Bahr and Song compared the funding of SCD with cystic fibrosis (CF), another 
genetic disorder that primarily affects whites. In 2012, NIH reported spending $65 
million on SCD compared to $86 million on CF, a disease with one third of the 
prevalence of SCD. Analysis of private funding from philanthropic support and grant 
income revealed that the Sickle Cell Disease Association of America  received $905,835 
while the Cystic Fibrosis Foundation received $134,090,038 in 2012  (Bahr & Song, 
2015).  
 Race must enter this conversation, as it is people of African descent and low SES 
that are most commonly affected by SCD worldwide (Palermo et al., 2008). Racial 
disparities in the quality of care in many types of cancers, HIV, and cardiac disease for 
AA have been extensively documented in the US (Bahr & Song, 2015). It is possible that 
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racial bias, intentional or unintentional, plays a factor in the lack of new therapies and 
funding for SCD. 
 The low SES status of most SCD patients may contribute to the lack of funding 
and interest.  SCD patients are generally poor, uninsured, and less educated.  
Pharmaceutical companies with strong financial ties to their stakeholders may not want to 
pursue treatment that is not profitable.  With less wealth and education, SCD patients also 
face barriers in reaching those in power and of public opinion (Bahr & Song, 2015). 
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FUTURE DIRECTIONS  
 
  
Standard practice for transfusion SCD patients is to match for Rh (D, E, C, c, e) 
and K antigens. Until further cost-benefit analyses are performed, extended antigen 
matching for Fy, Jk, Ss, and Rh variants should be reserved for patients who are already 
immunized with significant alloantibodies and or autoantibodies, while considering the 
availability of the antigen negative unit.  Equally important is the establishment of a 
nation-wide alloantibody registry to supplement transfusion services. Although hospital 
and transfusion services maintain historical alloantibody results, SCD patients commonly 
receive care at different sites. A complete and easily accessible alloantibody history is 
crucial is preventing alloimmunization.  
  There is considerable support for the need to engage minority communities to 
donate blood. Strategies to increase RBC donation among AA and other minorities 
should remain a top priority. They should be tailored personally to the individual need of 
each community with a focus on education and communication to build trust. For 
example, it is especially important to bring attention to female AA donors that low Hb is 
not a permanent disqualification and that they maybe be able to donate once their Hb 
level is higher. Theoretical frameworks can also be used to further understand blood 
donation practices in minority communities. Examples include the Assimilation Theory 
and Culture Fusion Theory, which highlights the effect of a person’s cultural identity on 
their actions (Renzaho & Polonsky, 2013; Spratling & Lawrence, 2019).   
As the cost of genotyping decreases, it would be possible to have blood group 
genotype of SCD patients even at birth. This information would be beneficial to identify 
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patients with rare blood group phenotypes, identify donors, and clarify antibody 
specificity. In parallel, ongoing studies can also identify susceptibility genes that 
contribute to SCD alloimmunization.  
As treatment options for treating DHTR and hyper-hemolysis in SCD patients are 
limited, ongoing research should explore novel approaches in alloimmunization and 
DHTR.  The case studies presented in this literature review represent preliminary 
evidence for the efficacy of rituximab, eculizumab, and tocilizumab.  Further prospective 
studies are necessary to demonstrate their efficacy, safety, side effects, and benefit/risk 
ratio. Evidence-based studies and clinical trials using a larger cohort population are 
necessary.  
It is imperative to prevent and diagnose DHTR because additional transfusions 
can precipitate hemolysis. However, the diagnosis and management of DHTR are not 
well developed. Many questions regarding DHTR remain unanswered: How should 
additional transfusions be administered? Is specific treatment for DHTR necessary? 
Studies to elucidate the mechanism of DHTR, particular triggers and markers of severity 
improve treatment of this condition.  
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